CDT Equity Inc. Company Profile
NASDAQ: CDTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 2:44 PM ET
CDT Equity at a glance
CDT Equity Inc. (NASDAQ: CDT) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Naples, FL. CDT Equity is led by Mr. James Bligh and employs about 4 people. The company's shares have traded publicly since 2022.
At a market capitalization of $32,432, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001896212, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does CDT Equity do?
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Business description based on the company's public filings.
Company information
- Legal name
- CDT Equity Inc.
- Ticker
- NASDAQ: CDT
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. James Bligh
- Employees
- 4
- Headquarters
- 4581 Tamiami Trail North, Naples, FL, United States
- Phone
- 646 491 9132
- Website
- cdtequity.com
- IPO year
- 2022
- Market cap
- $32.43K
- SEC CIK
- 0001896212
- Latest annual report
- 10-K · Apr 15, 2026
Companies similar to CDT Equity
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PBMPsyence Biomedical Ltd. | 4.99 | -2.54% | — | vs CDT |
| MDCXMedicus Pharma Ltd. | 0.0928 | -8.93% | $139.12K | vs CDT |
| SXTCChina SXT Pharmaceuticals Inc. Class A | 0.1326 | -61.42% | $175.22K | vs CDT |
| BDRXBiodexa Pharmaceuticals plc American Depositary Shs | 0.46 | -12.16% | $1.01M | vs CDT |
| SBFMSunshine Biopharma Inc. | 0.3401 | -20.91% | $1.47M | vs CDT |
| ARTLArtelo Biosciences Inc. | 3.27 | -3.12% | $1.79M | vs CDT |
| LABTLakewood-Amedex Biotherapeutics Inc. | 0.781 | -1.39% | $1.85M | vs CDT |
| OGENOragenics Inc. | 0.4839 | +1.30% | $2.18M | vs CDT |